Cornercap Investment Counsel Inc. Raises Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Cornercap Investment Counsel Inc. increased its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 4.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,002 shares of the specialty pharmaceutical company’s stock after purchasing an additional 959 shares during the quarter. Cornercap Investment Counsel Inc.’s holdings in Collegium Pharmaceutical were worth $677,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Altshuler Shaham Ltd purchased a new stake in Collegium Pharmaceutical during the fourth quarter worth about $28,000. Captrust Financial Advisors lifted its position in shares of Collegium Pharmaceutical by 97.5% during the 1st quarter. Captrust Financial Advisors now owns 2,151 shares of the specialty pharmaceutical company’s stock valued at $44,000 after acquiring an additional 1,062 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Collegium Pharmaceutical by 233.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,224 shares of the specialty pharmaceutical company’s stock worth $44,000 after acquiring an additional 1,558 shares in the last quarter. UBS Group AG grew its holdings in shares of Collegium Pharmaceutical by 300.0% in the 3rd quarter. UBS Group AG now owns 3,556 shares of the specialty pharmaceutical company’s stock worth $57,000 after acquiring an additional 2,667 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Collegium Pharmaceutical by 264.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,318 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 2,408 shares during the period.

Analyst Ratings Changes

A number of research firms have commented on COLL. Truist Financial boosted their target price on Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, February 26th. Jefferies Financial Group reaffirmed a “hold” rating and set a $37.00 price target (up previously from $30.00) on shares of Collegium Pharmaceutical in a research note on Thursday, January 4th. Needham & Company LLC reissued a “buy” rating and issued a $40.00 price objective on shares of Collegium Pharmaceutical in a research note on Thursday, April 11th. Piper Sandler restated an “overweight” rating and set a $39.00 target price (up from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Finally, StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Friday, March 29th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $39.00.

Collegium Pharmaceutical Trading Up 0.7 %

Shares of COLL stock opened at $35.40 on Wednesday. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of 30.00 and a beta of 1.03. The company has a current ratio of 1.17, a quick ratio of 1.10 and a debt-to-equity ratio of 2.48. The firm has a 50-day moving average price of $36.73 and a 200 day moving average price of $30.60. Collegium Pharmaceutical, Inc. has a twelve month low of $20.83 and a twelve month high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. The business had revenue of $149.75 million during the quarter, compared to the consensus estimate of $147.66 million. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. Research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.